+43.0%
ONDS vs GSK
+31.2%
+11.7%
-53.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | -1.9% | +1.8% | -1.2% |
| 7D | -3.5% | -1.8% | -1.7% | -4.5% |
| 30D | -14.1% | -2.2% | -11.9% | -14.8% |
| 3M | -36.3% | -1.8% | -34.5% | -36.4% |
| 6M | -27.5% | -10.6% | -16.9% | -32.0% |
| YTD | -21.9% | +4.4% | -26.4% | -12.7% |
| 1Y | +43.0% | +30.4% | +12.6% | +110.8% |
| All | +43.0% | +31.2% | +11.7% | +110.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling